TSRL Revenue and Competitors

Detroit, MI USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • TSRL's estimated annual revenue is currently $5.4M per year.(i)
  • TSRL's estimated revenue per employee is $271,350

Employee Data

  • TSRL has 20 Employees.(i)
  • TSRL grew their employee count by -13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$67.1M2676%$10.8MN/A
#2
$6.6M33-6%N/AN/A
#3
$4.8M24-4%N/AN/A
#4
$13.5M67-1%N/AN/A
#5
$17.1M85-13%N/AN/A
#6
$51.3M25516%N/AN/A
#7
$5.8M2916%N/AN/A
#8
$5.6M2812%N/AN/A
#9
$7.8M3918%N/AN/A
#10
$6M307%N/AN/A
Add Company

TSRL is a drug delivery company who provides proprietary technology solutions to enable the oral delivery of therapeutic agents that are challenged by poor solubility, low intestinal permeability and/or high first-pass clearance. Our technology concepts are derived from internal research, oral delivery consulting services to biotech and pharmaceutical companies as well as business development efforts. Once preclinical or clinical proof of concept of the delivery technology has been reached, TSRL is seeking to form strategic partnerships or out-license the technology for further development and commercialization.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$5.4M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TSRL News

2022-04-19 - Global Herpes Zoste Drug Market 2022 to 2028 Business ...

TSRL, Inc. The consumption and production data are used to determine the regional segments of Herpes Zoste Drug market. The regional study includes PESTEL...

2022-04-17 - Herpes Zoste Drug Market Size, Outlook And Forecast ...

... Foamix Pharmaceuticals Ltd., GeneOne Life Science, GlaxoSmithKline Plc, Merck & Co., NAL Pharmaceuticals Ltd., ReceptoPharm, TSRL, Inc.

2022-03-22 - Herpes Zoster Drug Market Size, Share, Application Analysis ...

... Novartis AG, Bristol-Myers Squibb Company, Sanofi, Merck & Co., Inc., AstraZeneca, Abbott, Astellas Pharma Inc., NAL Pharma, TSRL, Inc,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M20N/AN/A
#2
$2M20N/AN/A
#3
$15M200%$5M
#4
$2M205%N/A
#5
$3.4M2025%N/A

TSRL Executives


NameTitle
Elke LipkaPresident & CEO
Dawn ReynaChief Operating Officer
Elke LipkaPresident & CEO
John HilfingerPresident